ObsEva (NASDAQ:OBSV) & Acerus Pharmaceuticals (OTCMKTS:TRLPF) Financial Review

Earnings and Valuation

This table compares Acerus Pharmaceuticals and ObsEva”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acerus Pharmaceuticals	$7.38 million	7.71	-$18.79 million	($0.08)	-2.75
ObsEva	N/A	N/A	-$58.38 million	($0.92)	N/A

Acerus Pharmaceuticals has higher revenue and earnings than ObsEva. Acerus Pharmaceuticals is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Acerus Pharmaceuticals and ObsEva’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Acerus Pharmaceuticals	-254.66%	-346.72%	-94.54%
ObsEva	N/A	-416.36%	-92.01%

Volatility & Risk

Acerus Pharmaceuticals has a beta of 2.6, suggesting that its stock price is 160% more volatile than the S&P 500. Comparatively, ObsEva has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500.

Institutional and Insider Ownership

0.0% of Acerus Pharmaceuticals shares are held by institutional investors. Comparatively, 17.5% of ObsEva shares are held by institutional investors. 14.4% of ObsEva shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

About Acerus Pharmaceuticals

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.

About ObsEva

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.